* If you want to update the article please login/register
"Osteoporosis is also known as a silent disease in which bone mass and bone density loss does not cause apparent signs, resulting in inadequate treatment and preventive steps. " The bone mass and bone density loss gets more apparent over time, and only a small number of patients are diagnosed with OP-related fractures. Anti-OP drugs are now divided into three categories: antiresorptive agents, anabolic agents, and drugs with other methods.
Source link: https://doi.org/10.3389/fphar.2022.938447
"Specifically, drugs that can adversely affect bone health and immobilization related to acute and chronic diseases are often responsible for secondary osteoporosis, providing an indication to screen for bone mineral density and vertebral fractures. " Long-term studies in children chronically treated with steroids have resulted in the development of systematic ways to diagnose and treat pediatric osteoporosis. Pediatricians have a chance to promote bone mass accrual and musculoskeletal health in osteoporotic children as a result. What is New: U2022 Pediatricians have the opportunity to increase bone mass accrual and musculoskeletal stability in osteoporotic children and children at risk of osteoporosis. u2022 We have published an extensive but concise summary of osteoporosis risk factors and the medical examination of pediatric patients suspected of osteoporosis.
Source link: https://doi.org/10.1007/s00431-022-04455-2
"Objective: To assess bone antiresorptive effects of oleanoic acid in the rankl:HSE:CFPtransgenic medaka fish model for osteoporosis. Mean IM of larvae treated with OA at a concentration of 7. 5 u03bcM,12. 5 u03bcM, 15 bcM, 20 u03bcM, or 20 u03bcM (u03bcM) was significantly higher than that of alendronate-treated larvae, similar to alendronate-treated larvae. Conclusion: Oleanoic acid has bone protective action in the Rankl-induced osteoporosis medaka, and the bone protective effect is similar to alendronate.
Source link: https://doi.org/10.54928/vjop.v25i3.52
This is based on the fact that the older you get or the older you are, the more likely you are to experience autoimmune disease. " Osteoporosis is a disease with reduced bone mass density due to several causes, one of which is unhealthy diet. Osterosis-related arthritis among senior citizens is likely to rise the risk of osteoporosis. The researcher analyzed ten papers relating to the study of the elderly's osteoporosis knowledge based on these inclusion criteria. Although the majority of the respondents have good knowledge (75%), and respondents who have less information 20. 8 percent have more than 20%. Health cadres are expected to have more information about osteoporosis so that they can improve the elderly's knowledge and improve the elderly's health.
Source link: https://doi.org/10.36911/pannmed.v17i1.1246
"Objective: To determine the presence of sarcopenia in patients with osteoporosis. " The incidence of sarcopenia and acute sarcopenia in osteoporosis patients was between 31. 5% and 25. 9%, respectively. Sarcopenia and severe sarcopenia were both significantly higher in the osteoporosis group and in the non-osteoporosis group. Conclusion: The prevalence of sarcopenia inosteoporosis patients was high. The prevalence of sarcopenia in both the osteoporosis and non-oporosis groups increased as age advanced and male gender increased.
Source link: https://doi.org/10.54928/vjop.v25i3.56
Multiple exostotic chondrodysplasia and systemic osteoporosis have been reported by biopsy of bone marrow stromal cells obtained by biopsy of patients with systemic skeletal diseases in the iliac wing of patients with systemic skeletal disorders: multiple exostotic chondrodysplasia and systemic osteoporosis. Both the increased proliferative activity of the cultured cells themselves and the rise in the growth-stimulating effect of the autofeed have been reported. ".
Source link: https://doi.org/10.17816/vto64901
"The bone mineral density decreases bone mineral density and bone strength loss leads to fractures is characterized by osteoporosis. " Searching for new compounds that promote bone growth and their ability to repair seems to be a promising treatment for osteoporosis. Pre-osteoblasts and osteoclasts are among the many factors comparing the effect of polyrhodanine and its derivatives on the viability, morphology, and mitochondrial network. Our reports show that PRHD and its reduction of osteoclast function improves the pre-osteoblastu2019s proliferative skills and reduces osteoclast function while decreasing osteoclast activity. Through the ALP-OCL axis, improved expression of bone remodeling, namely osteopontin, osteocalcin, and alkaline phosphatase, can help establish the role of PRHD@MnFe2O4 in the promotion of differentiation of pre-osteoblasts. Based on these findings, PRHD@MnFe2O4 may be a promising osteoporosis treatment in the future, but further research is still needed. ".
Source link: https://doi.org/10.3390/ma15113990
"Abstract Purpose: To examine the effects of raloxifene, which is used for osteoporosis treatment and prevention, on invasive breast cancer in subgroups of postmenopausal women classified as risk factors for breast cancer. Experimental Design: The four-year Multiple Outcomes of Raloxifene Evaluation trial and a follow-up study, titled "Continuous Outcomes Relevant to Evista, were analyzed. Results: In the placebo group, an older age, elevated estradiol level, and a family history of breast cancer were all associated with an elevated breast cancer risk. Both women at lower and those at higher breast cancer risk were shown to have a reduced breast cancer risk. Raloxifene therapy was also associated with a reduced breast cancer risk in those women at risk for breast cancer. Conclusions: Raloxifene therapy was found to have a reduced risk of invasive breast cancer in postmenopausal women, regardless of the presence or absence of risk factors; its effect was even greater in women with a family history of breast cancer. ".
Source link: https://doi.org/10.1158/1078-0432.ccr-06-0688
"GnRH agonists increase bone turnover and reduce bone mineral density, a risk factor for fracture risk, consistent with this research. " In randomized controlled trials, bisphosphonates and selective estrogen receptor modulators increased bone mineral density in GnRH agonistu2013 treated men. Two ongoing large, random placebo-controlled studies will prospectively establish fracture incidence in men with prostate cancer and evaluate novel pharmacologic interventions during GnRH agonist therapy.
Source link: https://doi.org/10.1158/1078-0432.ccr-06-0846
"Abstract: "Abstract The aim of this research was to investigate the characteristics of postmenopausal women treated with teriparatide in Slovenia during the first decade after its approval, as well as predictors of bone mineral density increase with therapy. " After the first 12 months, high baseline PINP was associated with a rise in BMD at all locations. Despite long-term antiresorptive therapy, Teriparatide was mostly used to elderly women with significant osteoporosis who had suffered two or more fractures. With teriparatide, Baseline PINP may have predicted an initial BMD rise.
Source link: https://doi.org/10.1515/med-2021-0359
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions